LEUKOPENIA Symptoms and Causes

We are sorry, but no medical information on this topic currently exists in our database. Our articles are updated often, please revisit soon.

Check out the latest treatments for LEUKOPENIA

LEUKOPENIA treatment research studies

RIBASPHERE clinical trials, surveys and public health registries

Find Drug Side Effect reports


Fatigue (131)
Anaemia (129)
Depression (100)
Asthenia (95)
Dyspnoea (84)
Nausea (82)
Dizziness (67)
White Blood Cell Count Decreased (63)
Dehydration (62)
Headache (58)
Diarrhoea (53)
Vomiting (52)
Weight Decreased (51)
Anxiety (49)
Alopecia (49)
Insomnia (46)
Condition Aggravated (43)
Platelet Count Decreased (35)
Anger (34)
Chest Pain (34)
Arthralgia (34)
Haemoglobin Decreased (33)
Decreased Appetite (33)
Influenza Like Illness (31)
Pneumonia (30)
Red Blood Cell Count Decreased (29)
Pain (29)
Loss Of Consciousness (29)
Back Pain (28)
Anorexia (27)
Chills (26)
Rash (25)
Fall (25)
Blood Glucose Increased (25)
Crying (25)
Cough (24)
Suicidal Ideation (22)
Pyrexia (21)
Abdominal Pain (21)
Hypertension (21)
Feeling Abnormal (20)
Abdominal Pain Upper (19)
Disturbance In Attention (19)
Blood Potassium Decreased (19)
Irritability (17)
Pregnancy (16)
Confusional State (16)
Paranoia (16)
Myalgia (15)
Pruritus (15)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

LEUKOPENIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Evaluation of the Effects of Chinese Medical Treatment on Leucopenia After Chemotherapy in Breast Cancer Patients
Conditions: Leucopenia;   Breast Cancer
Interventions: Drug: Chinese medical treatment-LCH1;   Drug: Placebo
Outcome Measures: WBC Count;   Score of EORTC QLQ-C30
2 Unknown  Lifemel Honey to Reduce Leucopenia During Chemotherapy
Condition: Breast Cancer
Intervention: Behavioral: Lifemel honey intake every day
Outcome Measure: Prevention of myelotoxicity-every week during chemotherapy.
3 Recruiting Male Infertility Related With Post Infection Inflammatory Syndrome
Conditions: Male Infertility;   Leukopenia;   Postinfection Inflammation;   Oxidative Stress
Interventions: Drug: Prednisone;   Drug: Placebo
Outcome Measures: The number of live motile spermatozoa six month after the treatment;   biological markers
4 Unknown  Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy
Condition: Myelosuppression
Intervention: Dietary Supplement: Profonycia
Outcome Measure:
5 Recruiting Calcineurin-inhibitor Elimination/Reduction Randomized to Everolimus/Myfortic® vs Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction
Condition: Renal Transplant
Interventions: Drug: Arm 1 Everolimus/myfortic®;   Drug: Arm 2 Everolimus/Reduced dose tacrolimus
Outcome Measures: Renal function;   Graft survival;   Biopsy proven acute rejection;   Patient survival;   Impaired glucose tolerance;   Proteinuria;   Lipid levels;   Mouth ulcers;   Gastrointestinal complaints;   Leukopenia;   Thrombocytopenia;   Neurotoxicity;   Pneumonitis;   Cytomegalovirus;   Infection requiring hospitalization;   BK infection;   BK nephropathy;   Malignancies;   Cardiovascular complications;   Development of donor specific antibody
6 Unknown  A Pilot Study to Evaluate the Safety and Activities of EW02 in Reducing Neutropenia Caused by Chemotherapy
Conditions: Breast Cancer;   Chemotherapy;   Neutropenia
Intervention: Other: EW02
Outcome Measures: % change from Visit 5 (C2, Day 1) to Visit 7 (C2, Day 15) in WBC,;   % change from Visit 5 (C2, Day 1) to Visit 7 (C2, Day 15) in ANC;   QOL analysis using EORTC questionnaires ndex scores;   Inter-group comparison of Quality of Life survey collected for Cycle 2;   Within group analysis (based on "same person comparison"), on the change of WBC/ANC and QOL index scores
7 Unknown  Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients
Condition: Immunosuppression
Intervention: Drug: Myfortic
Outcome Measures: Incidence and severity of GI adverse events;   incidence and severity of bone marrow suppression (Leukopenia);   incidence of cytomegalovirus infection or disease
8 Recruiting Genomics of Kidney Transplantation
Condition: Kidney Transplantation
Outcome Measures: Transplant recipient genotypes: time to chronic graft disfunction;   Transplant recipient genotypes: time to a persistent 25% decrease in eGFR;   Transplant recipient genotypes: time to acute rejection;   Transplant recipient genotypes: time to allograft failure;   Donor Genotypes: time to chronic graft dysfunction;   Donor Genotype: time to a persistent 25% decrease in eGFR;   Donor Genotype: time to allograft failure;   For recipient genotypes, time to select mycophenolate-related toxicities (Leukopenia, anemia).;   Recipient genotypes: time to select CNI-related toxicities;   Recipient Genotypes: repeated measures of clinically obtained tacrolimus trough blood levels;   Recipient Candidate Genotypes: CN and IMPDH protein activity and expression.;   Time to composite endpoint of graft loss or death or persistent 25% increase in serum creatinine.;   Time to renal biopsy with presence of the following semi-quantitative pathology endpoints: patterns of Banff biopsy score, presence of circulating anti-donor anti-HLA antibodies, C4d positivity.;   Slope of eGFR.;   Delayed graft function.;   Time to EBV and CMV infection
9 Recruiting Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix
Conditions: Carcinoma of the Appendix;   Primary Peritoneal Cavity Cancer
Interventions: Drug: mitomycin C;   Drug: oxaliplatin;   Procedure: therapeutic conventional surgery;   Other: quality-of-life assessment;   Drug: hyperthermic intraperitoneal chemotherapy
Outcome Measures: Difference in the rate of grade 3 or 4 hematologic toxicities (Leukopenia, thrombocytopenia, and neutropenia) between the mitomycin C and oxaliplatin treatments;   Comparison of disease-free survival between the two treatment arms;   Comparison of overall survival between the two treatment arms;   Quality of life as assessed by FACT-G
10 Unknown  Diazoxide In the Management Of Hypoglycemic Neonates
Conditions: Infant, Newborn, Diseases;   Pregnancy in Diabetics;   Infant, Diabetic Mother;   Hypoglycemia;   Infant, Large for Gestational Age
Interventions: Drug: Diazoxide;   Drug: Ora-plus
Outcome Measures: Blood glucose measurement less than 2.0mmol/L;   Number of infants with significantly low blood glucose measurements (<1.5mmol/L).;   Length of stay for infants in hospital;   Need for intravenous dextrose infusion to maintain blood glucose above 2.0mmol/L;   Admission to neonatal intensive care unit (NICU);   Thrombocytopenia and/or Leukopenia;   Electrolyte imbalance requiring clinical intervention (intravenous or oral)
11 Unknown  A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients
Condition: Immunosuppression
Interventions: Drug: Myfortic;   Drug: CellCept
Outcome Measures: Incidence and severity of GI adverse events of Myfortic at 3 months;   assessment of GI tolerability using a GI symptom rating scale 2 weeks, 6 weeks, and 3 months after initiation of the drug;   incidence of biopsy-proven acute cellular rejection during the study period;   incidence of graft loss or death during the study period;   assessment of renal- and neurotoxic-sparing effects during the study period;   assessment of neurotoxic-sparing effects during the study period;   Incidence and severity of Leukopenia during the study period;   incidence of cytomegalovirus infection or disease during the study period
12 Recruiting HLA-Identical Sibling Renal Transplant Tolerance
Conditions: Immunosuppression;   Kidney Transplantation;   Graft Rejection
Intervention: Biological: Infusion of Donor Hematopoietic Stem Cells and Campath-1H
Outcome Measures: The ability to withdraw immunosuppression as above 24 months post-transplant with follow-up to 10 years.;   Patient and graft survival measured at the one-year timepoint post-transplant.;   Patient and graft survival measured at the three year timepoint post-transplant..;   Incidence rate of biopsy-proven acute rejection, defined as a renal biopsy demonstrating acute cellular or humoral rejection of Banff Grade IA or greater.;   Incidence of chronic allograft nephropathy, determined using renal biopsies and laboratory values, including 24 hour urine protein excretion.;   Incidence of graft versus host disease (GVHD).;   Incidence of adverse events associated w/ renal transplantation and immunosuppression, including infections, malignancies, post transplant lymphoproliferative disease (PTLD), thromboembolic events, hyperlipidemia, Leukopenia, thrombocytopenia, GI toxic
13 Not yet recruiting Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment
Conditions: Sickle Cell Disease;   Sickle Cell Anemia
Intervention: Drug: hydroxyurea
Outcome Measures: Cytopenia;   Development of infection evaluated by a physician at the point of care
14 Recruiting Role of Everolimus in Highly Sensitized Patients
Condition: Highly-sensitized Kidney Transplant Recipients
Intervention: Drug: everolimus + low-dose tacrolimus
Outcome Measures: The number of CMV and Polyomavirus BK infections;   Incidence of acute rejection and/or graft loss
15 Recruiting Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE
Condition: Advanced Hepatocellular Carcinoma
Interventions: Drug: Sorafenib;   Drug: sorafenib plus tegafur-uracil
Outcome Measures: time to progression (TTP):recist criteria;   progression free survival (PFS):recist criteria;   Time to symptomatic improvement:FHSI-8 questionnaire;   Quality of Life Using EQ-5D questionnaire.
16 Recruiting PTH - Preemptive Treatment for Herpesviridae
Condition: Viral Pneumonia
Interventions: Drug: Aciclovir;   Drug: Ganciclovir;   Drug: Placebo
Outcome Measures: Ventilator-free days at Day 60;   Day 60 mortality;   ICU mortality;   Hospital mortality;   Duration of mechanical ventilation in survivors;   Duration of ICU stay;   Duration of hospital stay;   Incidence of ventilator-associated pneumonia;   Incidence of bacteremia;   SOFA score;   Acute renal failure related to aciclovir or its placebo;   Leucopenia related to ganciclovir or its placebo;   Time to oropharyngeal negativation of HSV PCR;   Time to blood negativation of CMV PCR;   Incidence of herpetic bronchopneumonia;   Incidence of active CMV infection
17 Unknown  Everolimus on CKD Progression in ADPKD Patients
Condition: Polycystic Kidney Diseases
Interventions: Drug: Everolimus;   Drug: Standard Therapy
Outcome Measures: Reduction of GFR (according to MDRD formula) during a two-year follow up;   reduction of creatinine clearance and GFR (according to Cockcroft-Gault formula) during a two-year follow up;   changes in kidney size and renal and liver cysts dimensions evaluated by NMR at basal and at the end of the study;   safety profile of everolimus (leucopenia, thrombocytopenia, lipid profile and other adverse events;   evaluation of phosphatemia, phosphaturia and urinary cytokines on primary end point
18 Unknown  BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease
Conditions: Chagas Disease;   Trypanosomiasis;   Heart Disease
Interventions: Drug: Benznidazole;   Drug: Placebo
Outcome Measures: It will also evaluate the cardiovascular events of the large outcome trial, the first occurrence of any of the following clinically significant outcomes: Death;   Resuscitated cardiac arrest, requiring defibrillator or cardioversion;   Documented sustained ventricular tachycardia requiring cardioversion;   New development of symptomatic congestive heart failure;   Pacemaker or implantable cardiac defibrillator implantation;   Stroke or any other thromboembolic event in patients with no prior thromboembolic phenomena;   Heart Transplant;   New development of any of the following echo changes clinically indicated or done for the trial: Segmental wall motion abnormalities;   Ventricular aneurysm;   Reduction in left ventricular (LV) ejection fraction > 5%;   Increase in left ventricular diastolic dysfunction (LVDD) > 5.0 mm compared with baseline;   New 12 lead electrocardiogram (ECG) alterations (complete bundle branch block; fascicular block, advanced atrio-ventricular block, atrial fibrillation, etc.);   Progression of New York Heart Association (NYHA) functional class by at least one category;   Evaluation of safety (adverse events: dermatitis, peripheral neuropathy, gastro-intestinal intolerance, leucopenia [2500 x 10^9 L]), tolerance and adherence to treatment;   To determine the efficacy of benznidazole in patients with Chronic Chagas heart disease based on a 50% reduction in both qualitative and quantitative PCR.;   Safety and tolerability of benznidazole
19 Recruiting Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)
Condition: Metastatic Breast Cancer
Interventions: Drug: Lapatinib + 1,23 mg Eribulin;   Drug: Lapatinib + 1,76 mg Eribulin
Outcome Measures: Time to Progression (TTP);   Safety of the Therapy;   Toxicity of Therapy;   Objective Response Rate;   Overall Clinical Benefit Rate;   Overall Survival;   Assess PI3K mutation, PTEN expression and c-myc (Biomarkers) on primary tumor
20 Recruiting HIV Indicator Diseases Across Europe Study
Condition: HIV
Outcome Measure: Prevalence of HIV